[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tonix Pharm Holdings (TNXP)

Tonix Pharm Holdings (TNXP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 165,308
  • Shares Outstanding, K 15,941
  • Annual Sales, $ 13,110 K
  • Annual Income, $ -124,020 K
  • EBIT $ -151 M
  • EBITDA $ -149 M
  • 60-Month Beta 1.64
  • Price/Sales 12.02
  • Price/Cash Flow N/A
  • Price/Book 0.58

Options Overview Details

View History
  • Implied Volatility 152.45% (+15.08%)
  • Historical Volatility 74.24%
  • IV Percentile 86%
  • IV Rank 64.29%
  • IV High 187.25% on 03/05/26
  • IV Low 89.80% on 06/16/26
  • Expected Move (DTE 23) 1.11 (11.12%)
  • Put/Call Vol Ratio 0.07
  • Today's Volume 32
  • Volume Avg (30-Day) 910
  • Put/Call OI Ratio 0.20
  • Today's Open Interest 19,501
  • Open Int (30-Day) 14,972
  • Expected Range 8.84 to 11.05

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-2.71
  • Number of Estimates 3
  • High Estimate $-2.48
  • Low Estimate $-2.89
  • Prior Year $-3.86
  • Growth Rate Est. (year over year) +29.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.81 +1.33%
on 07/24/26
13.41 -25.88%
on 06/29/26
-3.28 (-24.81%)
since 06/26/26
3-Month
9.81 +1.33%
on 07/24/26
15.88 -37.41%
on 05/18/26
-2.77 (-21.79%)
since 04/28/26
52-Week
9.81 +1.33%
on 07/24/26
69.97 -85.79%
on 08/14/25
-37.36 (-78.99%)
since 07/28/25

Most Recent Stories

More News
Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026

BERKELEY HEIGHTS, N.J., July 27, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biotechnology company,...

TNXP : 9.94 (-4.15%)
Tonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Models

Data show clade IIb from 2022 outbreak is 100 to 100,000-fold less virulent than clade IIa from 2003 outbreak Three new models for investigating mpox infection and pathogenesis identified ...

TNXP : 9.94 (-4.15%)
Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA®

New agreement, effective January 1, 2027, to add approximately 9 million Medicare lives (16% of approximately 55 million Medicare lives in the U.S.) On top of two previously announced major commercial...

TNXP : 9.94 (-4.15%)
Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)

HORIZON is a potentially pivotal, randomized, double-blind, placebo-controlled Phase 2 study evaluating TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg as a first-line monotherapy in adults...

TNXP : 9.94 (-4.15%)
Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026

BERKELEY HEIGHTS, N.J., June 11, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully-integrated, commercial-stage biotechnology company, today...

TNXP : 9.94 (-4.15%)
Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. Lives

Agreement with second leading group purchasing organization (GPO), effective June 1, 2026, provides access to approximately 17 million additional U.S. commercial lives (10% of the ~177 million commercial...

TNXP : 9.94 (-4.15%)
Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

Real-world analysis of three years of closed claims data from Symphony Health, focused on the third year of the study (2023-2024), comprised of more than 261,000 U.S. adults with fibromyalgia Data...

TNXP : 9.94 (-4.15%)
Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology

Phase 1 data support TNX-1500 as a potentially first-in-class, best-in-class, third-generation anti-CD40L monoclonal antibody for the prevention of kidney transplant rejection Phase 2 investigator-initiated...

TNXP : 9.94 (-4.15%)
Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at The Professional Society for Health Economics and Outcomes Research (ISPOR) 2026 Annual Meeting

Real-world analysis of three years of closed claims data from Symphony Health focused on the third year of the study (2023-2024), comprised of more than 261,000 U.S. adults with fibromyalgia Data...

TNXP : 9.94 (-4.15%)
Tonix Pharmaceuticals to Present Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at ISPOR 2026

BERKELEY HEIGHTS, N.J., May 14, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, today announced...

TNXP : 9.94 (-4.15%)

Business Summary

Tonix Pharmaceuticals Holding Corp. is a specialty pharmaceutical company focused on developing new pharmaceutical products for CNS conditions. The Company develops therapies for disorders that include fibromyalgia syndrome and post-traumatic stress disorder. Its lead product candidates include TNX-102,...

See More

Key Turning Points

3rd Resistance Point 10.88
2nd Resistance Point 10.68
1st Resistance Point 10.31
Last Price 9.94
1st Support Level 9.74
2nd Support Level 9.54
3rd Support Level 9.17

See More

52-Week High 69.97
Fibonacci 61.8% 46.99
Fibonacci 50% 39.89
Fibonacci 38.2% 32.79
Last Price 9.94
52-Week Low 9.81

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.